F M Investments LLC Invests $2.73 Million in Blueprint Medicines Co. (NASDAQ:BPMC)

F M Investments LLC acquired a new position in Blueprint Medicines Co. (NASDAQ:BPMC) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 31,313 shares of the biotechnology company’s stock, valued at approximately $2,731,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP purchased a new stake in shares of Blueprint Medicines during the 3rd quarter valued at $32,000. R Squared Ltd purchased a new stake in Blueprint Medicines during the fourth quarter valued at about $51,000. Headlands Technologies LLC purchased a new stake in Blueprint Medicines during the fourth quarter valued at about $65,000. Asset Management One Co. Ltd. bought a new stake in Blueprint Medicines during the fourth quarter worth about $88,000. Finally, Van ECK Associates Corp boosted its holdings in shares of Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 363 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently weighed in on BPMC. Jefferies Financial Group started coverage on Blueprint Medicines in a research report on Monday, March 17th. They issued a “buy” rating and a $135.00 target price for the company. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They issued an “equal weight” rating and a $100.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $128.00 target price on shares of Blueprint Medicines in a research report on Friday, February 28th. JPMorgan Chase & Co. upped their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price objective on shares of Blueprint Medicines in a report on Tuesday. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $124.95.

Insiders Place Their Bets

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $102.28, for a total value of $511,400.00. Following the completion of the transaction, the director now owns 157,557 shares of the company’s stock, valued at approximately $16,114,929.96. The trade was a 3.08 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,608 shares of company stock valued at $3,319,587. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Stock Performance

Blueprint Medicines stock opened at $80.27 on Friday. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $5.13 billion, a P/E ratio of -74.32 and a beta of 0.75. The stock’s 50 day moving average is $91.56 and its 200 day moving average is $93.55.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities research analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.